Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications (MIRPROT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01681407|
Recruitment Status : Terminated (Insufficient microRNA for the analysis)
First Posted : September 10, 2012
Last Update Posted : June 19, 2015
A pilot study of mapping the peripheral plasma micro-RNA and proteomics patterns in depressive patients, treated with SSRI medications. It is an observational clinical bio-markers laboratory controlled research with no device.
The research includes two groups; one for patients diagnosed of having depression, and will get a standard SSRI medication regimen. Second group is for control subjects without depression. An option for a third group is planned to include first degree relatives of the depressed patients. After giving their informed consents, subjects and patients will go through standard clinical psychiatric interview, and routine clinical lab tests. Clinical standard, specific depression and anxiety questionnaires will be held at four follow-up meetings: at start; after 2 weeks; 4 weeks; and 10 weeks. Subjects and patients will be asked to give blood samples at these points of time for the lab processing: Complete plasma proteomics and specific micro-RNA levels.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||17 participants|
|Observational Model:||Case Control|
|Official Title:||Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||February 2014|
Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
Controls: Volunteers that had clinical screening with no depression diagnosis.
Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
- Depressive symptoms remission or response rates, under usual SSRI treatment. [ Time Frame: 10 weeks of follow up ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01681407
|HaEmek Medical Center|